Publicações COVID-19/DII
- Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2020:gutjnl-2020-322539.
- Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology 2020;159:481-491.e3.
- Brenner EJ, Ungaro RC, Colombel JF, et al. IBD in the COVID-19 era: the value of international collaboration. Lancet Gastroenterol Hepatol 2020;5:887-888.
- Brenner EJ, Pigneur B, Focht G, et al. BENIGN EVOLUTION OF SARS-CoV2 INFECTIONS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM TWO INTERNATIONAL DATABASES. Clin Gastroenterol Hepatol 2020.
- Brenner EJ, Kappelman MD. Working Together to Meet the Needs of Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020.
- Agrawal M, Brenner EJ, Zhang X et al. Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry. Inflamm Bowel Dis 2020.
